GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 254 ( ` in lakhs ) As at March 31, 2022 (n) Loan receivable from related party: GSK India Global Services Private Limited 190,00.00 ( ` in lakhs ) As at March 31, 2022 (o) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 32,88.04 GlaxoSmithKline Research & Development Ltd., U.K. 1,78.50 GlaxoSmithKline Services Unlimited, U.K. 81.07 Glaxo Operations UK Limited, U.K. 1,05.51 GlaxoSmithKline Export Limited, U.K. 12,96.32 GSK India Global Services Private Limited 3,59.05 ( ` in lakhs ) As at March 31, 2022 (p) Outstanding payables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 68,78.71 GlaxoSmithKline Export Limited, U.K. 16,12.21 GlaxoSmithKline Services Unlimited, U.K. 92.98 GlaxoSmithKline Asia Private Limited, India 30,03.53 ( ` in lakhs ) As at March 31, 2022 (q) Cross charges recoverable at the period end : GlaxoSmithKline Biologicals S.A., Belgium 8,50.00 ( ` in lakhs ) As at March 31, 2021 (r) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 1,57.35 GlaxoSmithKline Export Limited, U.K. 10,63.89 GlaxoSmithKline Research & Development Ltd, U.K. 15.70 GlaxoSmithKline Services Unlimited, U.K. 66.46 Glaxo Operations UK Limited, U.K. 1,32.05 GSK India Global Services Private Limited 2,83.84